Heart, Lung and Circulation
Volume 15, Issue 5 , Pages 320-324 , October 2006

Levosimendan for Weaning from Cardiopulmonary Bypass after Coronary Artery Bypass Grafting

Received 23 February 2006 ,Revised 30 May 2006 ,Accepted 31 May 2006.

References 

  1. Doll N, Fabricius A, Borger MA, Bucerius J, Doll S, Kramer K, et al. Temporary extracorporeal membrane oxygenation in patients with refractory postoperative cardiogenic shock, a single center experience. J Card Surg. 2003;18:512–518
  2. Lorell B. Mortality/incidence/prevalence of heart failure: current and projected clinical need for mechanical circulatory support. In:  Lorell B editors. The artificial heart: planning for evolving technologies. Bethesta, MD: National Institutes of Health; 1994;p. 9–14
  3. Noon GP, Akgul A. Ventricular assist devices in failing hearts. Turkiye Klinikleri J Cardiol. 2003;16(1):S95–S103
  4. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy. 2004;24(10):1366–1384
  5. Braun JP, Schneider M, Kastrup M, Liu J. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg. 2004;26(1):223–228
  6. Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail. 2005;7(7):1156–1163
  7. Nanas JN, Papazoglou PP, Terrovitis JV, Kanakakis J, Dalianis A, Tsolakis E, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94:1329–1332
  8. Nicks R, Cartmill T, Bernstein L. Hypoplasia of the aortic root. Thorax. 1970;25:339–346
  9. Innes CA, Wagstaff AJ. Levosimendan. A review of its use in the management of acute decompensated heart failure. Drugs. 2003;63(23):2651–2671
  10. Gravlee GP, Davis RF, Kurusz M, Utley JR. Cardiopulmonary bypass. Principles and practice. 2nd ed.. Philadelphia, PA: Lippincott Williams and Wilkins; 2000;p. 613–22
  11. Braunwald E, Kloner RA. The stunned myocardium: prolonged, post-ischemic ventricular dysfunction. Circulation. 1982;66:1146–1149
  12. Takeishi Y, Tono-Oka I, Kubota I, Braunwald E, Kloner RA. Functional recovery of hibernating myocardium after coronary artery bypass surgery: does it coincide with improvement in perfusion?. Am Heart J. 1991;122:665–670
  13. Ellis SG, Wynne J, Braunwald E, Henschke CI, Sandor T, Kloner RA. Response of reperfusion-salvaged, shinned myocardium to inotropic stimulation. Am Heart J. 1984;107:13–19
  14. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68(5):522–531
  15. Follath F, Cleland JG, Just H, Steering Committee, Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study . Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202
  16. Lehtonen LA, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187–203
  17. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology. 1994;81:974–987
  18. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8(1):105–110
  19. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005;7(5):882–887
  20. Nijhawan N, Nicolosi AC, Montgomery MW. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219–228
  21. Zimmermann N, Boknik G, Gams E, Herzig JW, Neumann J, Scholz H. Calcium sensitisation as a new principle of inotropic therapy in end-stage heart failure?. Eur J Cardiothorac Surg. 1998;14:70–75
  22. Braun JP, Jasulaitis D, Moshirzadeh M, Doepfiner UR, Kastrup M, von Heymann C, et al. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Crit Care. 2006;10:R17

☆ This study was presented at the 6th International Congress on Coronary Artery Disease: From Prevention to Intervention, Istanbul, Turkey, October 29-November 1, 2005.

PII: S1443-9506(06)00126-0

doi: 10.1016/j.hlc.2006.05.014

Heart, Lung and Circulation
Volume 15, Issue 5 , Pages 320-324 , October 2006

Article Tools

* Image Usage & Resolution